Omeros Corporation
corporate_fare Company Profile
Omeros Corporation (NASDAQ:OMER) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for OMER at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for OMER spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Omeros Slides 18% as Q3 Revenue Misses Despite Adjusted Beat
- Omeros Q3: YARTEMLEA Sales $35.9M, Net Loss $57.4M on Non-Cash Derivative Mark
- Omeros Posts $57.4M Third-Quarter Loss
- EU Regulator Rejects Narsoplimab Again, Closing Off European Market for Omeros
- Omeros Q2 2026: YARTEMLEA Sales Surge, Debt Repurchases Cut Dilution
Financial Snapshot
Short Interest & Short Volume
9.60 days to coverFINRA reported short interest of 12,833,757 shares in OMER as of the October 30, 2026 settlement, a 12.3% increase from the prior period — about 9.6 days to cover at its recent average daily volume. On November 20, 2026, 45.6% of OMER volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OMER, detected from its recent SEC filings · based on capital-structure filings through 2026-07-20.
Note Repurchase Completed · Total Debt Reduction
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →